Product Name: Albiglutide
CAS No: 782500-75-8
Purity: 95%
Molar Mass: 3283.6
Chemical Formula: C148H224N40O45
Synonyms: Albiglutide, Albugon, GSK 716155
Storage: Store at -20℃
Sequence: HGEGTFTSDV SSYLEGQAAK EFIAWLVKGR HGEGTFTSDV SSYLEGQAAKEFIAWLVKGR DAHKSEVAHR FKDLGEENFK ALVLIAFAQY LQQCPFEDHVKLVNEVTEFA KTCVADESAE NCDKSLHTLF GDKLCTVATL RETYGEMADCCAKQEPERNE CFLQHKDDNP NLPRLVRPEV DVMCTAFHDN EETFLKKYLYEIARRHPYFY APELLFFAKR YKAAFTECCQ AADKAACLLP KLDELRDEGKASSAKQRLKC ASLQKFGERA FKAWAVARLS QRFPKAEFAE VSKLVTDLTKVHTECCHGDL LECADDRADL AKYICENQDS ISSKLKECCE KPLLEKSHCIAEVENDEMPA DLPSLAADFV ESKDVCKNYA EAKDVFLGMF LYEYARRHPDYSVVLLLRLA KTYETTLEKC CAAADPHECY AKVFDEFKPL VEEPQNLIKQNCELFEQLGE YKFQNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCCKHPEAKRMPCAE DYLSVVLNQL CVLHEKTPVS DRVTKCCTES LVNRRPCFSALEVDETYVPK EFNAETFTFH ADICTLSEKE RQIKKQTALV ELVKHKPKATKEQLKAVMDD FAAFVEKCCK ADDKETCFAE EGKKLVAASQ AALGL
Target: GLP-1 RA
Application: Albiglutide(CAS: 782500-75-8) is a prominent pharmaceutical agent at the forefront of diabetes management. As a glucagon-like peptide-1 receptor agonist, Albiglutide exerts its therapeutic influence by enhancing insulin secretion in response to elevated blood glucose levels. This targeted mechanism positions Albiglutide as a crucial player in the treatment of type 2 diabetes, where precise glycemic control is paramount. Its clinical significance lies in its ability to improve glucose homeostasis, providing a valuable tool for healthcare professionals seeking effective solutions for diabetes patients. ,The pharmaceutical profile of Albiglutide extends to its role as a well-tolerated and long-acting therapeutic option. With its sustained-release formulation, Albiglutide offers the advantage of less frequent dosing, enhancing patient compliance and simplifying treatment regimens. The compound’s efficacy, coupled with its favorable pharmacokinetic profile, underscores its importance in the pharmaceutical landscape. As research and development continue to explore innovative solutions for diabetes care, Albiglutide stands as a testament to the ongoing pursuit of more effective and patient-friendly pharmaceutical interventions in the realm of metabolic disorders.
